Abstract
This case-control study investigated the absence of metabolic response to oxaliplatin-based therapy in progressive metastatic colorectal cancer as a possible risk factor. Ten patients were selected: five cases (metastatic colon cancer patients with disease progression at 6 months of receiving oxaliplatin-based therapy) and five controls (metastatic colon cancer patients with stable disease, disease with partial remission or disease with complete remission at 6 months of receiving oxaliplatinbased therapy). The results showed that the cases had significantly more exposure to absence of metabolic response compared to controls. Using Cox proportional hazards regression model, metastatic colon cancer patients exposed to metabolic response were found to have longer time to disease progression compared to metastatic colon cancer patients exposed to absence of metabolic response.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
